Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iressa and Docetaxel in Recurrent or Metastatic Advanced Non-Small Cell Lung Cancer
NCT00048087Phase 2Withdrawn
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Aug 2002
- Primary completion
- Jul 2003
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of gefitinib in non-small cell lung cancer (NSCLC), sponsored by University of Texas MD Anderson Cancer Center. Planned start Aug 2002; status: withdrawn.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00048087.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00048087.